New immunotherapy cocktails aim to outsmart resistant ovarian cancer

NCT ID NCT04918186

Recruiting now Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 4 times

Summary

This Phase 2 study tests several immunotherapy drug combinations in women with platinum-resistant high-grade serous ovarian cancer, a type that no longer responds to standard chemotherapy. About 60 participants will receive one of five immunotherapy regimens to see which best shrinks tumors or slows progression. The goal is to find promising combinations for larger future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab, BA3011, BA3021, ENB003, Toripalimab
What this could lead to: If successful, this could identify promising immunotherapy combinations to better control platinum-resistant ovarian cancer and guide larger future trials.
What could go wrong: This is an early Phase 2 platform study with only 60 participants. Not all drug combinations may prove effective, and side effects from immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

BCCA - Kelowna
NOT_YET_RECRUITING

Kelowna, British Columbia, V1Y 5L3, Canada
BCCA - Vancouver
NOT_YET_RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
NOT_YET_RECRUITING

Montreal, Quebec, H2X 3E4, Canada
Odette Cancer Centre
NOT_YET_RECRUITING

Toronto, Ontario, M4N 3M5, Canada
The University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University Health Network
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.